Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

350.30
+5.551.61%
Post-market: 348.00-2.3000-0.66%19:30 EDT
Volume:380.66K
Turnover:131.29M
Market Cap:9.76B
PE:-27.23
High:351.72
Open:343.00
Low:333.46
Close:344.75
52wk High:392.70
52wk Low:37.19
Shares:27.85M
Float Shares:24.08M
Volume Ratio:1.22
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:7.28
PE(LYR):-25.99

Loading ...

Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application

Dow Jones
·
Apr 14

Praxis says FDA accepts NDA review for essential tremor drug ulixacaltamide

Reuters
·
Apr 14

Praxis Precision Medicines Inc - FDA Sets Pdufa Target Action Date of January 29, 2027 for Ulixacaltamide

THOMSON REUTERS
·
Apr 14

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide Hcl in Patients With Essential Tremor

THOMSON REUTERS
·
Apr 14

Praxis Precision Medicines: Advancing CNS Pipeline and Near-Term Data Catalysts Support Buy Rating Despite Cash Burn

TIPRANKS
·
Apr 14

Praxis reports positive Phase 3 Essential3 trial results for ulixacaltamide in essential tremor

Reuters
·
Apr 13

Raymond James Initiates Praxis Precision Medicines at Strong Buy With $815 Price Target

MT Newswires Live
·
Apr 10

Praxis Precision initiated with a Strong Buy at Raymond James

TIPRANKS
·
Apr 10

Praxis: EMBRAVE Data Validate Elsunersen and De‑Risk Pipeline, Supporting Buy Rating on Favorable Risk‑Reward

TIPRANKS
·
Apr 07

Praxis reports positive elsunersen trial in pediatric epilepsies

TIPRANKS
·
Apr 07

FDA accepts Praxis relutrigine NDA for priority review, sets Sept. 27, 2026 decision date

Reuters
·
Apr 07

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali

Reuters
·
Apr 07

Praxis Precision Medicines: Advancing Late-Stage Neurology Pipeline Underpins Outperform Rating and $53 Price Target

TIPRANKS
·
Apr 07

Praxis Precision Med Price Target Maintained With a $843.00/Share by BTIG

Dow Jones
·
Apr 07

BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget

Reuters
·
Apr 06

BUZZ-Praxis Precision Medicines rises as epilepsy drug cuts seizures in children

Reuters
·
Apr 06

BRIEF-Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy

Reuters
·
Apr 06

Praxis says elsunersen cuts seizures 77% in SCN2A DEE EMBRAVE Part A trial

Reuters
·
Apr 06

Praxis Precision Medicines Inc - Elsunersen Well-Tolerated With No Drug-Related Serious Adverse Events up to 8 Mg

THOMSON REUTERS
·
Apr 06

Praxis Precision Medicines Announces Positive Results From the Embrave Part a Trial of Elsunersen in Patients With Scn2a Early-Onset Developmental and Epileptic Encephalopathy

THOMSON REUTERS
·
Apr 06